Selective HDAC6 inhibition for neurodegeneration and aging-related cellular dysfunction
PrimaryAugustine Therapeutics' core causal theory is that inhibiting the enzymatic function of HDAC6 can modify disease processes shared across peripheral and central nervous system disorders. The supporting review states that HDAC6 participates in neurodegeneration and aging-related cellular processes, and that pharmacologic inhibition or genetic reduction of HDAC6 has broad preclinical support in PNS and CNS indications. Testable predictions are that selective HDAC6 inhibitors should improve disease-relevant cellular phenotypes in neurologic or neuromuscular models, show efficacy in both peripheral and central nervous system disease models when exposure is matched to the target tissue, and produce biomarker evidence of HDAC6 pathway modulation.
Popperian evaluation
The premise is credible: HDAC6 is tied to neurodegeneration, aging-related cellular stress, and shared PNS/CNS pathology in the cited 2024 review. The weak point is causal depth. The evidence supports HDAC6 as a modulator, but the theory still assumes that catalytic inhibition alone captures enough of HDAC6 biology to change disease course during chronic treatment.
Supporting evidence: The review states that HDAC6 participates in neurodegeneration and aging-related cellular processes.; Pharmacologic inhibition and genetic knockout or knockdown of HDAC6 have broad preclinical support across PNS and CNS indications.; The theory distinguishes CNS use, which needs brain-penetrant inhibitors, from PNS use, where peripherally restricted compounds may be enough if tissue exposure is adequate.
Counter evidence: The evidence context is mainly preclinical and review-based.; The theory depends on the assumption that disease-relevant HDAC6 activity is sufficiently enzymatic for catalytic inhibition to produce therapeutic benefit.; The review flags chronic administration safety concerns for HDAC6 inhibitors.
The theory explains why one target could matter across neuropathy, CNS degeneration, and aging-linked cellular dysfunction: HDAC6 sits near shared stress processes rather than one disease label. That is useful, but broadness cuts both ways. Alternative explanations remain live, including model-specific effects, compound exposure differences, off-target pharmacology, and the possibility that HDAC6 marks damaged biology without driving enough of it.
Supporting evidence: The review describes common pathological hallmarks of PNS and CNS disorders that HDAC6 can modulate.; Both pharmacologic and genetic reduction studies support HDAC6 as a therapeutic strategy in preclinical PNS and CNS models.; HDAC6 PET tracers and biomarkers could connect target engagement to tissue-level effects, especially in CNS indications.
Counter evidence: The supplied evidence does not show that HDAC6 inhibition explains outcomes better than other stress-pathway interventions.; The theory has not yet shown human disease modification in the provided context.; Broad preclinical activity can come from shared model artifacts or general stress reduction rather than a disease-specific causal mechanism.
This is a testable theory. It predicts cellular phenotype rescue, efficacy in PNS and CNS models when exposure fits the target tissue, and biomarker evidence of HDAC6 pathway modulation. A clean failure pattern would hurt it: adequate exposure, confirmed pathway modulation, and no disease-relevant effect. The strongest version would predefine which biomarkers and phenotypes count before the experiment starts.
Supporting evidence: Selective HDAC6 inhibitors should improve disease-relevant cellular phenotypes in neurologic or neuromuscular models.; Selective HDAC6 inhibitors should show efficacy in both PNS and CNS disease models when exposure is matched to target tissue.; Treatment should produce biomarker evidence of HDAC6 pathway modulation.
Counter evidence: The predictions are still broad across many disorders and models.; The evidence context does not specify quantitative thresholds for exposure, biomarker change, or phenotype rescue.; A negative result could be blamed on compound class, tissue exposure, dosing, or model choice unless those criteria are locked in advance.
Reasoning tree
Public endorsements
The provided public quotes from Clara Campàs discuss biotech investing, sustainability criteria, European science, selectivity in investments, and personalized prevention. None of them mention Augustine Therapeutics, HDAC6, selective HDAC6 inhibition, or the theory that HDAC6 inhibition can modify neurodegenerative or aging-related cellular dysfunction. The listed company records mention Augustine Therapeutics, but the supplied excerpts do not show Campàs stating or endorsing the theory.
Koenig publicly ties Augustine to an HDAC6 inhibitor program and its clinical progress. He called Augustine's first clinical trial a major milestone, and he said the financing would take AGT-100216, Augustine's first HDAC6 inhibitor, into Phase 1. The webinar record also says he discussed the science behind Augustine's HDAC6 inhibitor. That is public mention of the theory area, but the material here does not show him explicitly stating the full causal claim about selective HDAC6 inhibition modifying shared neurodegenerative and aging-related disease processes across PNS and CNS.
Evidence publication IDs: 3253f527-5e36-4382-9e91-32956ed0ba36
Van Den Bosch is publicly tied to Augustine's scientific origin: the company pipeline is described as drawing on discoveries from his VIB lab, and an archived Augustine page says his lab's CMT research led to the company's creation. That is a public link to the program, but this dossier does not show him directly endorsing the specific HDAC6 inhibition theory in his own words.
Evidence publication IDs: 4b293802-dcee-41f4-a2bd-e1ac5bb4dc91
Rie Schultz Hansen publicly backed the company's HDAC6 program when she said, "As we advance our pipeline of novel HDAC6 inhibitors towards the clinic..." That is not a neutral mention. It is a direct statement, in her role as CSO, that Augustine's HDAC6 inhibitor approach is worth developing clinically. The quote does not restate the full PNS/CNS and aging mechanism, but it clearly supports the core therapeutic theory rather than contradicting it.